Allakos Inc. (ALLK): Price and Financial Metrics

Allakos Inc. (ALLK): $7.44

0.17 (+2.34%)

POWR Rating

Component Grades













Add ALLK to Watchlist
Sign Up

Industry: Biotech



in industry

ALLK Stock Price Chart Interactive Chart >

Price chart for ALLK

ALLK Price/Volume Stats

Current price $7.44 52-week high $11.73
Prev. close $7.27 52-week low $2.54
Day low $7.18 Volume 313,800
Day high $7.57 Avg. volume 1,552,763
50-day MA $6.28 Dividend yield N/A
200-day MA $4.77 Market Cap 633.92M

Allakos Inc. (ALLK) Company Bio

Allakos Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. The company was founded in 2012 and is based in San Carlos, California.

ALLK Latest News Stream

Event/Time News Detail
Loading, please wait...

ALLK Latest Social Stream

Loading social stream, please wait...

View Full ALLK Social Stream

Latest ALLK News From Around the Web

Below are the latest news stories about ALLAKOS INC that investors may wish to consider to help them evaluate ALLK as an investment opportunity.

Allakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting

– Siglec-10 is a myeloid checkpoint receptor selectively expressed on tumor associated macrophages and dendritic cells –– AK007 potently blocks all known ligand interaction with Siglec-10, including the “don’t eat me” signal CD24 –– Monotherapy treatment with a Siglec-10 antagonist antibody polarized tumor-associated myeloid cells and reduced tumor burden in pre-clinical studies – SAN CARLOS, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology co

Yahoo | November 10, 2022

Allakos Provides Business Update and Reports Third Quarter 2022 Financial Results

SAN CARLOS, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the third quarter ended September 30, 2022. Recent Allakos Events Allakos’s lirentelimab clinical development is focused on atopic dermatitis and chronic spontaneous urticaria. Initiated a Phase 2b randomized,

Yahoo | November 7, 2022

Alkermes, Allakos, and Other Stocks See Action From Activist Investors

Sarissa Capital disclosed a large stake in pharmaceutical firm Alkermes. New Enterprise Associates more than doubled its investment in clinical-stage drug firm Allakos.

Yahoo | October 14, 2022

3 Healthcare Stocks to Sell Before They Die

Troubled healthcare companies will have much more difficulty surviving, so identifying healthcare stocks to sell is very important.

Larry Ramer on InvestorPlace | September 30, 2022

After losing 95% in the past year, Allakos Inc. (NASDAQ:ALLK) institutional owners must be relieved by the recent gain

A look at the shareholders of Allakos Inc. ( NASDAQ:ALLK ) can tell us which group is most powerful. And the group that...

Yahoo | September 24, 2022

Read More 'ALLK' Stories Here

ALLK Price Returns

1-mo 24.83%
3-mo 87.41%
6-mo 148.00%
1-year -7.10%
3-year -23.24%
5-year N/A
YTD -24.00%
2021 -30.07%
2020 46.81%
2019 82.44%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.615 seconds.